Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
2.
J Glaucoma ; 27(5): 445-449, 2018 05.
Article in English | MEDLINE | ID: mdl-29521718

ABSTRACT

PURPOSE: To investigate the clinical efficacy and safety profile of micropulse transscleral cyclophotocoagulation (MP-CPC) in patients with refractory glaucoma. MATERIALS AND METHODS: Retrospective case series of 79 consecutive patients who underwent MP-CPC at the Wills Eye Hospital from March 23, 2014 to June 23, 2016 and who had at least 3 months of follow-up. Treatment success was defined as an intraocular pressure (IOP) of 6 to 21 mm Hg or a reduction of IOP by 20%. Failure was defined as an inability to meet the criteria for success, need for retreatment >3 times, or need for incisional glaucoma surgery. RESULTS: Patients had a mean follow-up time of 7.8±4.5 months. The mean IOP before MP-CPC was 31.9±10.2 mm Hg. The IOP was reduced by an average of 51% at the last follow-up and the mean number of IOP lowering medications was reduced from 2.3 at baseline to 1.5 at last follow-up. Treatment success rates were 75% at 3 months, 66% at 6 months, and 67% at last follow-up. Complications of MP-CPC included 7 patients with hypotony (8.8%), 21 patients with prolonged anterior chamber inflammation (1+ cell or flare for >3 mo, 26%), 13 patients with loss of ≥2 lines of best-corrected visual acuity at 3 months (17%), 4 patients with macular edema (5%), 2 patients with corneal edema and 2 patients with phthisis. CONCLUSIONS: MP-CPC is an effective treatment for patients with refractory glaucoma. Shorter treatment times with more frequent repeat treatments, if necessary, should be considered given the incidence of significant vision loss in this study.


Subject(s)
Glaucoma/surgery , Laser Coagulation/adverse effects , Laser Coagulation/methods , Aged , Aged, 80 and over , Ciliary Body/pathology , Ciliary Body/surgery , Female , Follow-Up Studies , Glaucoma/epidemiology , Glaucoma/pathology , Humans , Intraocular Pressure/physiology , Laser Coagulation/statistics & numerical data , Male , Middle Aged , Postoperative Complications/epidemiology , Postoperative Complications/etiology , Retrospective Studies , Sclera/pathology , Sclera/surgery , Treatment Failure , Treatment Outcome , Visual Acuity
3.
J Glaucoma ; 27(3): 246-250, 2018 03.
Article in English | MEDLINE | ID: mdl-29303877

ABSTRACT

PURPOSE: Phacoemulsification has been cited as a possible cause of bleb failure in eyes with prior trabeculectomy. No method has been developed to directly evaluate the risk of bleb failure after phacoemulsification. We investigate the use of trypan blue during cataract surgery in the setting of a preexisting trabeculectomy to evaluate the functional status of the bleb and predict postoperative bleb function. MATERIALS AND METHODS: In total, 14 patients contributing 1 eye each with a history of prior trabeculectomy with mitomycin C undergoing phacoemulsification with intraocular lens implantation were enrolled in this prospective, nonrandomized clinical trial. At the time of phacoemulsification, trypan blue was instilled into the anterior chamber before capsulorhexis creation. Staining of the bleb was grouped as being mild or diffuse using intraoperative photographs. These eyes were followed for 1 year postoperatively and evaluated for intraocular pressure (IOP) control. RESULTS: The change in IOP was not significantly different between the 2 groups (P=0.14). A trend towards greater need for IOP-lowering medications was noted (P<0.10) in eyes with mild bleb staining. No statistically significant difference in rates of decreased bleb function was noted at 1-year follow-up after phacoemulsification. CONCLUSION: The intensity of bleb staining with trypan blue during phacoemulsification is not associated with changes in IOP postoperatively. A trend towards decreased need for IOP-lowering medications was noted in eyes with diffuse bleb staining at 1 year after cataract surgery.


Subject(s)
Coloring Agents/administration & dosage , Phacoemulsification/methods , Surgically-Created Structures/physiology , Trypan Blue/administration & dosage , Aged , Aged, 80 and over , Alkylating Agents/administration & dosage , Combined Modality Therapy , Conjunctiva/drug effects , Female , Follow-Up Studies , Humans , Intraocular Pressure/physiology , Lens Implantation, Intraocular , Male , Mitomycin/administration & dosage , Postoperative Complications , Prospective Studies , Staining and Labeling , Tonometry, Ocular , Trabeculectomy/methods
4.
J Glaucoma ; 27(1): e14-e16, 2018 01.
Article in English | MEDLINE | ID: mdl-29088054

ABSTRACT

PURPOSE: To assess the viability of a manufactured high-density polyethylene patch graft material (Su-Por) for prevention of tube shunt exposure. MATERIALS AND METHODS: Retrospective review of the first 11 patients from the Wills Eye Hospital Glaucoma Service to receive the high-density polyethylene patch graft during tube shunt surgery. RESULTS: Four patients (36.3%) experienced an extrusion of the Su-Por patch without a leak within 2.5 months of postoperative follow-up. All 4 patients developed either symptomatic or progressive extrusion. Operative repair was completed with Su-Por removal and replacement with a new human donor patch graft. No patient developed any sign of infection despite the extrusions. The remaining 7 patients had an uneventful postoperative course and continue to have no complications from the Su-Por patch with 9 months of follow-up. CONCLUSIONS: Given the high rate of extrusion of the Su-Por graft, this material seems to be an inadequate alternative for covering tube shunts. Harvested human tissue or other more flexible, manufactured grafts remain the standard of care for covering tube shunts.


Subject(s)
Glaucoma Drainage Implants , Glaucoma, Open-Angle/surgery , Polyethylene , Prosthesis Failure , Corneal Transplantation , Glaucoma, Open-Angle/physiopathology , Humans , Intraocular Pressure/physiology , Pericardium/transplantation , Pilot Projects , Reoperation , Retrospective Studies , Tissue Donors
5.
Surv Ophthalmol ; 60(3): 229-41, 2015.
Article in English | MEDLINE | ID: mdl-25639795

ABSTRACT

Vitreous block (VB), a rare secondary angle-closure caused by anterior rotation of the ciliary body, occurs in a variety of settings, but most frequently after glaucoma filtering surgery. The etiology remains unclear, but choroidal expansion and anterior vitreous abnormalities have been proposed. In the past, treatment of VB has yielded high rates of failure and recurrence. Advancements in surgical techniques, however, have led to improved visual outcomes. We review the history of this condition and present a stepwise approach to its diagnosis and treatment using modern imaging modalities and surgical techniques.


Subject(s)
Aqueous Humor/metabolism , Ciliary Body/drug effects , Glaucoma, Angle-Closure/therapy , Uveal Diseases/therapy , Vitreous Body/pathology , Ciliary Body/pathology , Diuretics, Osmotic/therapeutic use , Drainage , Glaucoma, Angle-Closure/etiology , Glaucoma, Angle-Closure/metabolism , Humans , Incidence , Laser Coagulation , Mydriatics/therapeutic use , Risk Factors , Uveal Diseases/complications , Vitrectomy
6.
Graefes Arch Clin Exp Ophthalmol ; 252(8): 1179-88, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24888380

ABSTRACT

PURPOSE: To review the existing technology for self-tonometry and evaluate methods for continuous monitoring of IOP currently undergoing development and clinical trials in humans. BACKGROUND: Glaucoma is one of the leading causes of blindness worldwide. Current glaucoma therapy is focused primarily on lowering intraocular pressures (IOP). Decisions to modify treatment regiments are primarily based on office IOP. Since IOP fluctuates throughout the day, values obtained in the office may be a poor representation of the patient's disease. IOP measurements outside of the physician's office environment would provide better knowledge of the disease state and allow for better-informed medical decision making. METHODS AND RESULTS: We performed a literature search using Medline and IEEE database for studies investigating technologies that have been developed for continuous 24-hour IOP monitoring. CONCLUSION: There is currently no technology that has been approved for use to allow for continuous monitoring of IOP fluctuations. New experimental technology being developed and currently undergoing clinical trials has demonstrated potential for changing the diagnosis and management of glaucoma.


Subject(s)
Glaucoma/diagnosis , Intraocular Pressure/physiology , Monitoring, Ambulatory , Telemetry/methods , Tonometry, Ocular/methods , Humans , Self Care/methods
7.
Biol Blood Marrow Transplant ; 17(4): 524-33, 2011 Apr.
Article in English | MEDLINE | ID: mdl-20457264

ABSTRACT

We undertook a prospective longitudinal study to examine humoral and cellular immune responses to influenza vaccination in hematopoietic cell transplant (HCT) patients and healthy adults. Healthy volunteers and HCT patients had blood samples taken prior to influenza vaccination and 30, 90, and 180 days postvaccination. Serum from pre- and postvaccination time points were tested for influenza A IgG and IgM by ELISA as well as tested for neutralizing antibody (NAb) titers via hemagglutination inhibition assay. Polychromatic flow cytometry was used to examine CD4(+) T cells for levels of interferon (IFN)-γ, tumor necrosis factor (TNF)-α, and CD154 (CD40 ligand) expression after stimulation with inactivated flu virus. In healthy subjects, we found a significant increase in Influenza A IgG and IgM levels as well as an increase in NAb titers pre- and post-influenza vaccination. Notably, NAb titers of most HCT patients did not rise to a protective level postvaccination. CD4(+) T cell expression of CD154 and cytokine responses were significantly reduced in HCT recipients compared to healthy adults. A lack of B cell reconstitution and dysfunctional CD4 T cell costimulation (as marked by low CD154 expression) is associated with low NAb levels postvaccination in HCT patients.


Subject(s)
Antibodies, Neutralizing/blood , Antibodies, Viral/blood , CD4-Positive T-Lymphocytes/metabolism , CD40 Ligand/blood , Gene Expression Regulation , Influenza, Human/blood , Influenza, Human/prevention & control , Stem Cell Transplantation , Vaccination , Adult , Aged , Antibodies, Neutralizing/immunology , Antibodies, Viral/immunology , CD4-Positive T-Lymphocytes/immunology , Female , Humans , Immunoglobulin G/blood , Immunoglobulin G/immunology , Immunoglobulin M/blood , Immunoglobulin M/immunology , Influenza, Human/immunology , Interferon-gamma/blood , Interferon-gamma/immunology , Male , Middle Aged , Transplantation, Homologous , Tumor Necrosis Factor-alpha/blood , Tumor Necrosis Factor-alpha/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...